Through combining in silico analysis with in vitro validation, seven ECMGs (i.e. LAMA3, ITGB6, ITGB4, ITGA2, LAMC2, and COL11A1) were confirmed to be considerably up-modulated in pancreatic cancer cell lines and clinical samples and were strongly associated with the prognosis and tumor stage of the patients. The gene discussed is ITGB6; the disease is neoplasm.